We are live on
!
Find out more
TECP
Trails Edge Capital Partners Portfolio holdings
AUM
$630M
This Fund
S&P 500
This Quarter
Est. Return
+55.36%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$405M
AUM Growth
–
Cap. Flow
+$350M
Cap. Flow
% of AUM
86.44%
Top 10 Holdings %
Top 10 Hldgs %
68.52%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$33.9M |
| 2 |
Vaxcyte
PCVX
|
+$33M |
| 3 |
DFTX
Definium Therapeutics
DFTX
|
+$31.8M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$25.1M |
| 5 |
Nurix Therapeutics
NRIX
|
+$25M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Acadia Pharmaceuticals
ACAD
$5.27B
| $37.9M | 9.37% |
+1,419,406
| New | +$33.9M |
|
|
DFTX
2
Definium Therapeutics
DFTX
$6.02B
| $34.4M | 8.5% |
+2,568,110
| New | +$31.8M |
|
|
3
Vaxcyte
PCVX
$9.09B
| $34M | 8.41% |
+737,470
| New | +$33M |
|
|
4
Nurix Therapeutics
NRIX
$2.8B
| $33.1M | 8.17% |
+1,743,220
| New | +$25M |
|
|
LBRX
5
LB Pharmaceuticals
LBRX
$1.57B
| $31.1M | 7.68% |
+1,395,608
| New | +$24.4M |
|
|
6
Xenon Pharmaceuticals
XENE
$5.85B
| $26.8M | 6.61% |
+597,092
| New | +$25.1M |
|
7
Immunocore
IMCR
$1.93B
| $23.7M | 5.85% |
+682,597
| New | +$24.1M |
|
8
Arcus Biosciences
RCUS
$4.02B
| $21.8M | 5.4% |
+916,313
| New | +$18.7M |
|
9
Tyra Biosciences
TYRA
$1.59B
| $18.4M | 4.55% |
+700,000
| New | +$12.9M |
|
10
Neurogene
NGNE
$817M
| $16.2M | 4% |
+785,000
| New | +$19.5M |
|
|
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
| $14.9M | 3.67% |
+1,043,313
| New | +$10.2M |
|
12
Apogee Therapeutics
APGE
$10.2B
| $14.5M | 3.58% |
+192,000
| New | +$12.1M |
|
13
Inhibikase Therapeutics
IKT
$349M
| $12.7M | 3.13% |
+6,178,124
| New | +$9.83M |
|
|
IVA
14
Inventiva
IVA
$1.11B
| $12.4M | 3.05% |
+2,657,997
| New | +$12.4M |
|
15
CAMP4 Therapeutics
CAMP
$279M
| $12.2M | 3% |
+1,983,986
| New | +$8.44M |
|
|
TERN
16
DELISTED
Terns Pharmaceuticals
TERN
| $12.1M | 2.99% |
+300,000
| New | +$6.93M |
|
17
X4 Pharmaceuticals
XFOR
$412M
| $10.3M | 2.54% |
+2,571,478
| New | +$9.34M |
|
|
MBX
18
MBX Biosciences
MBX
$3.3B
| $9.94M | 2.46% |
+315,158
| New | +$7.65M |
|
19
vTv Therapeutics
VTVT
$134M
| $9.24M | 2.28% |
+231,000
| New | +$6.43M |
|
20
Compass Therapeutics
CMPX
$456M
| $7.6M | 1.88% |
+1,415,273
| New | +$6.54M |
|
21
Immunovant
IMVT
$8.99B
| $6.1M | 1.51% |
+240,165
| New | +$5.36M |
|
22
Enliven Therapeutics
ELVN
$4.47B
| $3.07M | 0.76% |
+199,306
| New | +$3.97M |
|
23
Mirum Pharmaceuticals
MIRM
$5.98B
| $2.52M | 0.62% |
+31,862
| New | +$2.29M |
|
Similar funds
SJIC
SFO
PPC
ACGA
FAM
MC
GPTE
KNW
Trails Edge Capital Partners's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Trails Edge Capital Partners, which disclosed 23 positions worth $405M. Its ten largest holdings account for 69% of the portfolio.
Its largest position is Acadia Pharmaceuticals: 1,419,406 shares worth $37.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Trails Edge Capital Partners's largest Q4 2025 buy was Acadia Pharmaceuticals: 1,419,406 shares worth $37.9M.
- Trails Edge Capital Partners's ten largest holdings make up 69% of its $405M portfolio in Q4 2025.
- Trails Edge Capital Partners disclosed 23 positions in Q4 2025, its first 13F filing on record.
Based on Trails Edge Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.